Medindia
Medindia LOGIN REGISTER
Advertisement

Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

Monday, October 2, 2017 Clinical Trials News
Advertisement
- Trigriluzole did not differentiate from placebo on the primary endpoint or key secondary outcome measure at the end of the 8-week randomization phase.

Sponsored Post and Backlink Submission


Latest Press Release on Clinical Trials News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close